Acetoacetate and beta-hydroxybutyrate in combination with other metabolites release insulin from INS-1 cells and provide clues about pathways in insulin secretion.
Mitochondrial anaplerosis is important for insulin secretion, but only some of the products of anaplerosis are known. We discovered novel effects of mitochondrial metabolites on insulin release in INS-1 832/13 cells that suggested pathways to some of these products. Acetoacetate, beta-hydroxybutyrate, alpha-ketoisocaproate (KIC), and monomethyl succinate (MMS) alone did not stimulate insulin release. Lactate released very little insulin. When acetoacetate, beta-hydroxybutyrate, or KIC were combined with MMS, or either ketone body was combined with lactate, insulin release was stimulated 10-fold to 20-fold the controls (almost as much as with glucose). Pyruvate was a potent stimulus of insulin release. In rat pancreatic islets, beta-hydroxybutyrate potentiated MMS- and glucose-induced insulin release. The pathways of their metabolism suggest that, in addition to producing ATP, the ketone bodies and KIC supply the acetate component and MMS supplies the oxaloacetate component of citrate. In line with this, citrate was increased by beta-hydroxybutyrate plus MMS in INS-1 cells and by beta-hydroxybutyrate plus succinate in mitochondria. The two ketone bodies and KIC can also be metabolized to acetoacetyl-CoA and acetyl-CoA, which are precursors of other short-chain acyl-CoAs (SC-CoAs). Measurements of SC-CoAs by LC-MS/MS in INS-1 cells confirmed that KIC, beta-hydroxybutyrate, glucose, and pyruvate increased the levels of acetyl-CoA, acetoacetyl-CoA, succinyl-CoA, hydroxymethylglutaryl-CoA, and malonyl-CoA. MMS increased incorporation of (14)C from beta-hydroxybutyrate into citrate, acid-precipitable material, and lipids, suggesting that the two molecules complement one another to increase anaplerosis. The results suggest that, besides citrate, some of the products of anaplerosis are SC-CoAs, which may be precursors of molecules involved in insulin secretion.
MacDonald
Michael J
MJ
Children Diabetes Center, Univesity of Wisconsin School of Medicine and Public Health, Madison, WI, USA. mjmacdon@wisc.edu
Longacre
Melissa J
MJ
Stoker
Scott W
SW
Brown
Laura J
LJ
Hasan
Noaman M
NM
Kendrick
Mindy A
MA
D020155:3-Hydroxybutyric Acid / Q000378:metabolism* / Q000494:pharmacology; D000090:Acetoacetates / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D045744:Cell Line, Tumor; D019343:Citric Acid / Q000378:metabolism; D002952:Citric Acid Cycle / Q000187:drug effects / Q000502:physiology; D004734:Energy Metabolism / Q000502:physiology*; D005232:Fatty Acids, Volatile / Q000378:metabolism; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000378:metabolism*; D007651:Keto Acids / Q000378:metabolism / Q000494:pharmacology; D007657:Ketone Bodies / Q000378:metabolism; D008928:Mitochondria / Q000378:metabolism*; D019289:Pyruvic Acid / Q000378:metabolism / Q000494:pharmacology; D051381:Rats; D015398:Signal Transduction / Q000502:physiology
D000090:Acetoacetates; D005232:Fatty Acids, Volatile; D007328:Insulin; D007651:Keto Acids; D007657:Ketone Bodies; D019343:Citric Acid; C016635:acetoacetic acid; C013082:alpha-ketoisocaproic acid; D019289:Pyruvic Acid; D020155:3-Hydroxybutyric Acid